Pituitary apoplexy in endocrinologically silent adenoma during somatostatin analog administration for pancreatic neuroendocrine tumor: A case report
- 15 December 2023
- journal article
- research article
- Published by Wiley in Neuropathology
- Vol. 44 (3) , 247-251
Abstract
A dopamine agonist administered for prolactinoma treatment and pituitary stimulation tests are reported as risk factors for pituitary apoplexy. We report a case of an 82‐year‐old patient who suffered from pituitary apoplexy in an endocrinologically silent adenoma during lanreotide administration. The patient was diagnosed with a pancreatic neuroendocrine tumor with lymph node metastasis and treated with lanreotide for two years. An endoscopic endonasal transsphenoidal approach was used for tumor and hematoma removal. The specimen showed growth hormone and prolactin positivity and was diagnosed as pit1‐lineage plurihormonal adenoma. The tumor also showed positivity for somatostatin receptor 2. Thus, lanreotide treatment is a risk factor for pituitary apoplexy even in silent adenoma.Keywords
This publication has 9 references indexed in Scilit:
- Pituitary apoplexy causing spontaneous remission of acromegaly following long-acting octreotide therapy: a rare drug side effect or just a coincidenceOxford Medical Case Reports, 2016
- Pituitary ApoplexyEndocrine Reviews, 2015
- Lanreotide in Metastatic Enteropancreatic Neuroendocrine TumorsNew England Journal of Medicine, 2014
- Pituitary apoplexy after somatostatin analogue administration: coincidental or causative?Clinical Endocrinology, 2013
- Somatostatin receptors: From signaling to clinical practiceFrontiers in Neuroendocrinology, 2013
- Quantitative analysis of somatostatin receptor subtype (SSTR1–5) gene expression levels in somatotropinomas and non-functioning pituitary adenomasEuropean Journal of Endocrinology, 2007
- Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centreEuropean Journal of Endocrinology, 2001
- Somatotropinoma Infarction During Octreotide Therapy Leading to Bilateral Cavernous Sinus SyndromePituitary, 2000
- Somatostatin analogue treatment of neuroendocrine tumoursPostgraduate Medical Journal, 1996